Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening

被引:0
|
作者
Abedellatif, Saif-Eldin [1 ]
Hosni, Racha [1 ]
Waha, Andreas [2 ]
Gielen, Gerrit H. [2 ]
Banat, Mohammed [3 ]
Hamed, Motaz [3 ]
Gueresir, Erdem [3 ]
Froehlich, Anne [4 ]
Sirokay, Judith [4 ]
Wulf, Anna-Lena [1 ]
Kristiansen, Glen [1 ]
Pietsch, Torsten [2 ]
Vatter, Hartmut [3 ]
Hoelzel, Michael [5 ]
Schneider, Matthias [3 ]
Toma, Marieta Ioana [1 ]
机构
[1] Univ Hosp Bonn, Inst Pathol, D-53127 Bonn, Germany
[2] Univ Hosp Bonn, Inst Neuropathol, D-53127 Bonn, Germany
[3] Univ Hosp Bonn, Dept Neurosurg, D-53127 Bonn, Germany
[4] Univ Hosp Bonn, Dept Dermatol, D-53127 Bonn, Germany
[5] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
关键词
melanoma; brain metastases; BRAF; organoids; DABRAFENIB;
D O I
10.3390/pharmaceutics16081042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and aims: Brain metastases are prevalent in the late stages of malignant melanoma. Multimodal therapy remains challenging. Patient-derived organoids (PDOs) represent a valuable pre-clinical model, faithfully recapitulating key aspects of the original tumor, including the heterogeneity and the mutational status. This study aimed to establish PDOs from melanoma brain metastases (MBM-PDOs) and to test the feasibility of using them as a model for in vitro targeted-therapy drug testing. Methods: Surgical resection samples from eight patients with melanoma brain metastases were used to establish MBM-PDOs. The samples were enzymatically dissociated followed by seeding into low-attachment plates to generate floating organoids. The MBM-PDOs were characterized genetically, histologically, and immunohistologically and compared with the parental tissue. The MBM-PDO cultures were exposed to dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) followed by a cell viability assessment. Results: Seven out of eight cases were successfully cultivated, maintaining the histological, immunohistological phenotype, and the mutational status of the parental tumors. Five out of seven cases harbored BRAF V600E mutations and were responsive to BRAF and MEK inhibitors in vitro. Two out of seven cases were BRAF wild type: one case harboring an NRAS mutation and the other harboring a KIT mutation, and both were resistant to BRAF and MEK inhibitor therapy. Conclusions: We successfully established PDOs from melanoma brain metastases surgical specimens, which exhibited a consistent histological and mutational profile with the parental tissue. Using FDA-approved BRAF and MEK inhibitors, our data demonstrate the feasibility of employing MBM-PDOs for targeted-therapy in vitro testing.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
    He, Xingfeng
    Jiang, Yan
    Zhang, Long
    Li, Yaqi
    Hu, Xiang
    Hua, Guoqiang
    Cai, Sanjun
    Mo, Shaobo
    Peng, Junjie
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
  • [2] Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening
    Li, Zhichao
    Xu, Haibo
    Gong, Yanqing
    Chen, Wei
    Zhan, Yonghao
    Yu, Lei
    Sun, Yangyang
    Li, Aolin
    He, Shiming
    Guan, Bao
    Wu, Yucai
    Xiong, Gengyan
    Fang, Dong
    He, Yuhui
    Tang, Qi
    Yao, Lin
    Hu, Zheng
    Mei, Hongbing
    He, Zhisong
    Cai, Zhiming
    Guo, Yinglu
    Li, Xuesong
    Zhou, Liqun
    Huang, Weiren
    ADVANCED SCIENCE, 2022, 9 (04)
  • [3] Patient-derived organoids in translational oncology and drug screening
    Yang, Ruixin
    Yu, Yingyan
    CANCER LETTERS, 2023, 562
  • [4] Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report
    Prieto, Isabel
    Barbachano, Antonio
    Rodriguez-Salas, Nuria
    Vinal, David
    Cortes-Guiral, Delia
    Munoz, Alberto
    Fernandez-Barral, Asuncion
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (01) : 442 - 449
  • [5] Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening
    Gamboa, Christian Moya
    Jara, Kelly
    Pamarthy, Sahithi
    Liu, Liqiong
    Aiken, Robert
    Xiong, Zhenggang
    Danish, Shabbar
    Sabaawy, Hatem E.
    STAR PROTOCOLS, 2021, 2 (01):
  • [6] A preclinical screening platform of patient-derived tumor organoids for drug discovery in hepatocellular carcinoma.
    Nuciforo, Sandro
    Blukacz, Lauriane
    Matter, Matthias S.
    Soysal, Savas D.
    Kollmar, Otto
    Wieland, Stefan
    Heim, Markus H.
    SWISS MEDICAL WEEKLY, 2021, 151 : 4 - 4
  • [7] Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma
    Antonia, Ricardo J.
    Toriguchi, Kan
    Karelehto, Eveliina
    Annuar, Dania
    Timmerman, Luika
    Tbeileh, Noura
    Mattis, Aras N.
    Corvera, Carlos U.
    Hirose, Kenzo
    Nakakura, Eric K.
    Donner, David B.
    Warren, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] A HIGH CONTENT SCREENING PLATFORM FOR TESTING IMMUNOTHERAPIES IN PATIENT-DERIVED ORGANOIDS
    Goverse, Gera
    de Man, Saskia
    Veenendaal, Tomas
    Beztsinna, Nataliia
    Okkes, Daniel
    Weterings, Ashgard
    Yan, Kuan
    Price, Leo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A74 - A74
  • [9] Drug screening of non-small cell lung cancer patient-derived organoids in a microwell platform
    Luan, Qiyue
    Pulido, Ines
    Zhou, Jian
    Shimamura, Takeshi
    Papautsky, Ian
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Patient-derived organoids for personalized gallbladder cancer modelling and drug screening
    Yuan, Bo
    Zhao, Xiaofang
    Wang, Xiang
    Liu, Erdong
    Liu, Chunliang
    Zong, Yali
    Jiang, Youhai
    Hou, Minghui
    Chen, Yao
    Chen, Lei
    Zhang, Yongjie
    Wang, Hongyang
    Fu, Jing
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (01):